RxDoctor Payments Data

Shruti Patel, MD

Gastroenterology · Milford, DENPI 1558616755

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Johnson & Johnson at 35.4% of the total. That places this record below the midpoint for gastroenterology clinicians in DE, where the typical reported total is $2,631.

$305in general payments, 2019–2025

Across 13 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$108
  • AbbVie$52
  • Aimmune Therapeutics, Inc.$31
  • Madrigal Pharmaceuticals$27
  • Ardelyx, Inc.$26
  • Takeda Pharmaceuticals U.S.A., Inc.$26
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$305100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$305 in reported general payments places this provider in the 10th percentile of 50 gastroenterology providers in Delaware.

See all gastroenterology providers in Delaware

Medicare billing

Part B allowed, 2024
$85,557
Medicare patients
367
Services billed
761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide49$48,041
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates152$10,734
Lubiprostone16$4,643
Pantoprazole Sodium141$2,788
Ursodiol13$1,532
Esomeprazole Magnesium20$1,184
Omeprazole42$891
Famotidine28$390
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl12$208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$52$48,04149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 50 gastroenterology providers in Delaware.

Other gastroenterology in Milford

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →